Skip to content

Comparision the effect of adjuvant Reminfentanil, Dexmedetomidine or metoral with thiopental on hemodynamic status in patients with major depressive disorder candidates for electroconvulsive therapy

Comparision the effect of adjuvant Reminfentanil, Dexmedetomidine or metoral with thiopental on hemodynamic status in patients with major depressive disorder candidates for electroconvulsive therapy

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20141209020258N178
Enrollment
90
Registered
2022-12-31
Start date
2023-01-20
Completion date
Unknown
Last updated
2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

major depressive disorder candidates for electroconvulsive therapy. Mood disorder due to known physiological condition with major depressive-like episode

Interventions

Intervention 1: Intervention group1: Before induction of anesthesia, 100 micrograms of remifentanil is injected intravenously. Intervention 2: Intervention group 2: Before the induction of anesthesia,

Sponsors

Arak University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: All patients with major depressive disorder are candidates for ETC Consent to participate in the study 18 to 60 years Body mass index 20 to 30 Patients with major depressive disorder who do not have other psychiatric illnesses at the same time. No history of underlying heart, lung, kidney and liver diseases No history of recent CVA or MI Insensitivity to Remifentanil or Dex Medtomidine or Metoral or Thiopental All patients who are indicated to receive ECT according to psychiatric treatment criteria. Absence of pregnancy and breastfeeding

Exclusion criteria

Exclusion criteria: All patients who experience cardiorespiratory arrest during ECT. All patients who need intubation after ECT due to prolonged apnea and respiratory failure All patients who do not experience sufficient and desired seizures during ECT. All patients who want to withdraw from the study or do not want to continue electroshock therapy.

Design outcomes

Primary

MeasureTime frame
Average blood pressure. Timepoint: Recovery. Method of measurement: Barometer.;Average heart rate. Timepoint: Recovery. Method of measurement: Pulse oximeter.;Average percentage of oxygen saturation,. Timepoint: Recovery. Method of measurement: Pulse oximeter.;Patient satisfaction. Timepoint: Recovery. Method of measurement: Question.;Agitation. Timepoint: Recovery. Method of measurement: Physical examination.;Seizure duration. Timepoint: Recovery. Method of measurement: Observation.;Recovery period. Timepoint: Recovery. Method of measurement: Observation.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Anita Alaghemand

Arak University of Medical Sciences

Alaghemand@arakmu.ac.ir+98 86 3222 2003

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026